Your browser doesn't support javascript.
loading
Postoperative chemotherapy relative dose intensity and overall survival in patients with colon cancer.
Brown, Justin C; Meyerhardt, Jeffrey A; Yang, Shengping; Caan, Bette J.
Afiliación
  • Brown JC; Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA, 70808, USA. Justin.Brown@pbrc.edu.
  • Meyerhardt JA; LSU Health Sciences Center New Orleans School of Medicine, 1901 Perdido St, New Orleans, LA, 70112, USA. Justin.Brown@pbrc.edu.
  • Yang S; Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, 533 Bolivar St, New Orleans, LA, 70112, USA. Justin.Brown@pbrc.edu.
  • Caan BJ; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.
Article en En | MEDLINE | ID: mdl-38520557
ABSTRACT

PURPOSE:

Quantifying the association of chemotherapy relative dose intensity (RDI) with overall survival may enable supportive care interventions that improve chemotherapy RDI to estimate their magnitude of potential clinical benefit.

METHODS:

This cohort study included 533 patients with stage II-III colon cancer who initiated a planned regimen of 12 cycles of 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. The primary exposure was chemotherapy RDI. The primary outcome was overall survival. Restricted cubic splines estimated hazard ratios (HR).

RESULTS:

Chemotherapy regimen RDI was associated with overall survival in an L-shaped pattern (linear P = 0.006; nonlinear P = 0.057); the risk of death was flat above 85% but increased linearly below 85%. For example, a decrease in RDI from 85 to 75% was associated with an increased risk of death [HR 1.20 (95% CI 1.08, 1.52)], whereas an increase in RDI from 85 to 95% was not associated with the risk of death [HR 1.06 (95% CI 0.82, 1.38)].

CONCLUSION:

If chemotherapy RDI is considered a potential surrogate of overall survival, supportive care interventions that improve chemotherapy RDI might confer a potential clinical benefit in this population.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancer Chemother Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancer Chemother Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania